selegiline has been researched along with Drug Withdrawal Symptoms in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (38.89) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Charkhpour, M; Ghaderi, M; Habibi-asl, B; Hassanzadeh, K; Parvizpour, A; Shakhsi, M | 1 |
| Barclay, E; Goyarzu, P; Magallanes, N; Malin, DH; Mathews, H; Mills, WR; Moon, WD; Negrete, AP; Stephens, B; Vela, AJ | 1 |
| Everhart, T; Harris, DS; Jacob, P; Jones, RT; Lin, E; Mendelson, JE | 1 |
| Bryson, SW; Fong, D; Fortmann, SP; Hayward, C; Killen, DT; Killen, JD; Lowenthal, K; Murphy, GM; Schatzberg, AF | 1 |
| George, TP; Termine, A; Vessicchio, JC | 1 |
| Castro, A; Dapena, MD; Linazasoro, G; Van Blercom, N | 1 |
| Grasing, K; He, S; Li, N | 1 |
| Grasing, K; He, S | 2 |
| Bigelow, GE; Garner, JE; Ginn, DH; Haberny, KA; Setoda, D; Walsh, SL; Wilkins, JN | 1 |
| Alexoff, D; Fowler, JS; Logan, J; MacGregor, RR; Pappas, N; Schyler, D; Shea, C; Volkow, ND; Wang, GJ; Wolf, AP | 1 |
| Bravi, D; Chase, TN; Davis, TL; Mouradian, MM; Roberts, JW | 1 |
| Gitlin, MJ | 1 |
| Ghosh, S; Grasing, K | 1 |
| Churchyard, A; Lees, AJ; Mathias, CJ | 1 |
| Busenbark, K; Hauser, RA; Hubble, JP; Koller, WC; Malapira, T; Olanow, CW | 1 |
| Bizzarri, G; Calzetti, S; Negrotti, A | 1 |
| Nickel, B; Schulze, G; Szelenyi, I | 1 |
8 trial(s) available for selegiline and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion.
Topics: Administration, Cutaneous; Adult; Affect; Amphetamine; Amphetamines; Analysis of Variance; Cocaine; Dopamine Uptake Inhibitors; Drug Interactions; Female; Homovanillic Acid; Humans; Infusions, Intravenous; Male; Methamphetamine; Methoxyhydroxyphenylglycol; Monitoring, Physiologic; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phenethylamines; Prolactin; Selegiline; Statistics, Nonparametric; Substance Withdrawal Syndrome; Young Adult | 2009 |
Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Behavior Therapy; Breath Tests; Carbon Monoxide; Female; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Monoamine Oxidase Inhibitors; Motivation; Recurrence; Regression Analysis; Selegiline; Sex Distribution; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Treatment Outcome; Young Adult | 2010 |
Smoking cessation and panic attacks: a report of 2 cases.
Topics: Double-Blind Method; Female; Humans; Middle Aged; Monoamine Oxidase Inhibitors; Panic Disorder; Placebos; Risk Factors; Selective Serotonin Reuptake Inhibitors; Selegiline; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder | 2002 |
Absence of acute cocaine interactions with the MAO-B inhibitor selegiline.
Topics: Administration, Oral; Adult; Arousal; Blood Pressure; Cocaine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Euphoria; Heart Rate; Humans; Infusions, Intravenous; Male; Monoamine Oxidase Inhibitors; Reflex, Pupillary; Selegiline; Substance Withdrawal Syndrome; Substance-Related Disorders | 1995 |
Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal.
Topics: Aged; Brain; Female; Humans; Kinetics; Male; Middle Aged; Models, Biological; Monoamine Oxidase; Parkinson Disease; Selegiline; Substance Withdrawal Syndrome; Tomography, Emission-Computed | 1994 |
Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Blood Pressure; Dizziness; Drug Therapy, Combination; Epinephrine; Female; Head; Heart Rate; Humans; Hypotension, Orthostatic; Male; Middle Aged; Norepinephrine; Parkinson Disease; Posture; Prospective Studies; Selegiline; Severity of Illness Index; Substance Withdrawal Syndrome; Time Factors | 1999 |
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline; Substance Withdrawal Syndrome | 2000 |
Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Female; Humans; Male; Middle Aged; Motor Activity; Parkinson Disease; Selegiline; Severity of Illness Index; Single-Blind Method; Substance Withdrawal Syndrome | 2001 |
10 other study(ies) available for selegiline and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Repeated central administration of selegiline attenuated morphine physical dependence in rat.
Topics: Animals; Infusions, Intraventricular; Male; Morphine; Morphine Dependence; Naloxone; Rats; Rats, Sprague-Dawley; Rats, Wistar; Selegiline; Substance Withdrawal Syndrome; Substance-Related Disorders | 2013 |
Inhibition of monoamine oxidase isoforms modulates nicotine withdrawal syndrome in the rat.
Topics: Animals; Brain; Clorgyline; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Isoenzymes; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nicotine; Rats; Rats, Sprague-Dawley; Selegiline; Smoking Cessation; Substance Withdrawal Syndrome | 2013 |
Subthalamic deep brain stimulation masking possible malignant syndrome in Parkinson disease.
Topics: Analgesics, Non-Narcotic; Anti-Infective Agents; Antiparkinson Agents; Combined Modality Therapy; Consciousness Disorders; Dantrolene; Deep Brain Stimulation; Diagnosis, Differential; Diagnostic Errors; Dystonic Disorders; Encephalitis; Female; Fluid Therapy; Foot; Humans; Levodopa; Malignant Hyperthermia; Middle Aged; Muscle Relaxants, Central; Parkinson Disease; Selegiline; Substance Withdrawal Syndrome; Tachycardia | 2004 |
Selegiline modifies the extinction of responding following morphine self-administration, but does not alter cue-induced reinstatement, reacquisition of morphine reinforcement, or precipitated withdrawal.
Topics: Animals; Cues; Extinction, Psychological; Male; Morphine; Rats; Rats, Wistar; Reinforcement, Psychology; Selegiline; Self Administration; Substance Withdrawal Syndrome | 2005 |
Effects of high-dose selegiline on morphine reinforcement and precipitated withdrawal in dependent rats.
Topics: Acoustic Stimulation; Analgesics, Opioid; Animals; Conditioning, Operant; Cues; Dopamine; Eating; Male; Monoamine Oxidase Inhibitors; Morphine; Morphine Dependence; Motor Activity; Naloxone; Narcotic Antagonists; Photic Stimulation; Rats; Rats, Wistar; Reinforcement Schedule; Reinforcement, Psychology; Selegiline; Self Administration; Substance Withdrawal Syndrome | 2005 |
L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action.
Topics: Animals; Behavior, Animal; Body Weight; Central Nervous System Stimulants; Clorgyline; Conditioning, Operant; Extinction, Psychological; Indans; Male; Methamphetamine; Monoamine Oxidase Inhibitors; Morphine; Morphine Dependence; Rats; Rats, Wistar; Reinforcement, Psychology; Selegiline; Self Administration; Substance Withdrawal Syndrome | 2006 |
End-of-dose dystonia in Parkinson's disease.
Topics: Adult; Carbidopa; Dystonia; Humans; Infusions, Intravenous; Levodopa; Middle Aged; Parkinson Disease; Selegiline; Substance Withdrawal Syndrome | 1993 |
Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome.
Topics: Adult; Bipolar Disorder; Cyclohexanols; Dose-Response Relationship, Drug; Humans; Male; Monoamine Oxidase Inhibitors; Myoclonus; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Selegiline; Substance Withdrawal Syndrome; Syndrome; Venlafaxine Hydrochloride | 1997 |
Selegiline prevents long-term changes in dopamine efflux and stress immobility during the second and third weeks of abstinence following opiate withdrawal.
Topics: Animals; Dopamine; Male; Morphine; Rats; Rats, Wistar; Restraint, Physical; Selegiline; Stress, Physiological; Substance Withdrawal Syndrome | 1998 |
Effect of enantiomers of deprenyl (selegiline) and amphetamine on physical abuse liability and cortical electrical activity in rats.
Topics: Amphetamine; Animals; Body Weight; Cerebral Cortex; Codeine; Electric Conductivity; Electroencephalography; Evoked Potentials; Female; Isomerism; Rats; Rats, Inbred Strains; Reference Values; Selegiline; Substance Withdrawal Syndrome | 1990 |